KCNN4 and sickle cell disease: Although no human diseases involving KCa3.1 mutations have been described so far, KCa3.1 constitutes a very attractive and (in some cases) relatively well-validated drug target for diseases or conditions ranging from sickle cell disease, restenosis, and atherosclerosis to asthma and traumatic brain injury (see [40] for a recent review).